scholarly journals Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia

PLoS ONE ◽  
2020 ◽  
Vol 15 (10) ◽  
pp. e0240880
Author(s):  
Dawit Wolday ◽  
Dorsisa Legesse ◽  
Yazezew Kebede ◽  
Dawd S. Siraj ◽  
Joseph A. McBride ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Viral Suppression ◽  
Immune Recovery ◽  
Sustained Viral Suppression ◽  
Hiv 1

scholarly journals Monocyte Dysfunction, Activation, and Inflammation After Long-Term Antiretroviral Therapy in an African Cohort

2019 ◽  
Vol 220 (9) ◽  
pp. 1414-1419 ◽  
Author(s):  
Rose Nabatanzi ◽  
Lois Bayigga ◽  
Stephen Cose ◽  
Sarah Rowland Jones ◽  
Moses Joloba ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Viral Suppression ◽  
Mononuclear Cells ◽  
Peripheral Blood Mononuclear ◽  
Fatty Acid Binding ◽  
Sustained Viral Suppression ◽  
Immunodeficiency Virus ◽  
And Function ◽  
Hiv Negative

Abstract Background Monocyte dysfunction may persist during antiretroviral therapy (ART). Methods Frozen peripheral blood mononuclear cells of 30 human immunodeficiency virus (HIV)-infected ART-treated adults with sustained viral suppression and CD4 counts ≥500 cells/µL were consecutively analyzed for monocyte phenotypes and function. Results Nonclassical monocytes (CD14+, CD16++), interleukin (IL)-1β production, and expression of CD40 and CD86 were lower among ART-treated HIV-infected adults relative to age-matched HIV-negative adults (P = .01, P = .01, and P = .02, respectively). Intestinal fatty acid-binding protein, IL6, and soluble CD14 were higher among HIV-infected adults relative to HIV-negative adults (P = .0002, P = .04, and P = .0017, respectively). Conclusions Further investigation is required to understand drivers of persistent monocyte activation and dysfunction.

scholarly journals Sustained Viral Suppression and Immune Recovery in HIV Type 1--Infected Children after 4 Years of Highly Active Antiretroviral Therapy

2005 ◽  
Vol 40 (4) ◽  
pp. 604-608 ◽  
Author(s):  
P. L. A. Fraaij ◽  
G. Verweel ◽  
A. M. C. van Rossum ◽  
E. G. van Lochem ◽  
M. Schutten ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Viral Suppression ◽  
Immune Recovery ◽  
Highly Active ◽  
Sustained Viral Suppression ◽  
Hiv Type 1

scholarly journals Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam

2017 ◽  
Vol 20 (4) ◽  
pp. e25030 ◽  
Author(s):  
Junko Tanuma ◽  
Shoko Matsumoto ◽  
Sebastien Haneuse ◽  
Do Duy Cuong ◽  
Tuong Van Vu ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Viral Suppression ◽  
Immune Recovery ◽  
First Line ◽  
Infected Adult

scholarly journals CRISPR/Cas9-Induced Mutagenesis Corroborates the Role of Transportin-SR2 in HIV-1 Nuclear Import

2021 ◽  
Author(s):  
Julie Janssens ◽  
Jolien Blokken ◽  
Yulia Lampi ◽  
Flore De Wit ◽  
Irena Zurnic Bonisch ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Nuclear Import ◽  
Viral Suppression ◽  
Combination Antiretroviral Therapy ◽  
Viral Loads ◽  
Sustained Viral Suppression ◽  
Induced Mutagenesis ◽  
Hiv 1

Combination antiretroviral therapy (cART) effectively controls HIV-1 by reducing viral loads, but it does not cure the infection. Lifelong treatment with cART is a prerequisite for sustained viral suppression.

Sign in / Sign up

Export Citation Format

Share Document